Lindsay S. Ackerman, MD, FAAD

Monitoring Schedule for JAK Inhibitors in Atopic Dermatitis

Video content above is prompted by the following:

What is the recommended monitoring schedule for JAKi? Do you communicate it with patients when selecting treatment?

Videos

Lindsay S. Ackerman, MD, FAAD, and Jonathan Silverberg, MD, PhD, MPH, provide clinical insights on best practices for monitoring patients with atopic dermatitis who are receiving JAK inhibitors.

Safety Profile of JAK Inhibitors and their Use in Atopic Dermatitis

Discuss safety of JAKi compared to traditional and more advanced treatments for atopic dermatitis.

What are primary concerns for physicians and patients?

Experts on atopic dermatitis compare the safety profile of JAK inhibitors with traditional and more advanced treatments currently available for patients.

A panel of dermatologists discuss the evolution of JAK inhibitors for atopic dermatitis and how they fit into current treatment paradigms.

JAK Inhibitors in Atopic Dermatitis

A number of JAK inhibitors, both oral (abrocitinib, upadacitnib) and topical (ruxolitinib cream), are FDA approved for atopic dermatitis.

How have JAK inhibitors evolved over the years?

How have differences between JAK inhibitors led to differences in their safety and efficacy profiles?


Focusing on the complex pathophysiology of atopic dermatitis, Lindsay S. Ackerman, MD, FAAD, discusses the importance of looking beyond type 2 inflammation while treating patients.

Looking Beyond Type 2 Inflammation in Atopic Dermatitis

With better understanding of the pathophysiology of atopic dermatitis, how important is to look beyond type 2 inflammation?

Lindsay S. Ackerman, MD, FAAD

Articles